Skip to Content

Clinical Trial Details

A Rand, Ph III Study Comparing Conventional Dose Tx Using a Combination of Lenalidomide, Bortezomib, & Dexamethasone (RVD) to High-Dose Tx with Peripheral Stem Cell Transplant in the Initial mgmt of Myeloma in Pts up to 65 Years of Age.


In this research study, we are looking to explore the drug combination, lenalidomide, bortezomib and dexamethasone alone or when combined with autologous stem cell transplantation to see what side effects it may have and how well it works for treatment of newly diagnosed multiple myeloma. Read More  >>

IRB Protocol Number
DFCI 10-106

Clinical Trial Categories

  • Myeloma
Barbara Beauchemin, RN, BSN at 603-224-2556


  • Payson Center for Cancer Care
    250 Pleasant Street
    Concord, NH 03301
    Main: 603-230-6000